Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Proactive Investors

23 Jul 2026, 07:41 UTC · 1h ago

Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Scancell Holdings PLC has agreed to an all-share merger with Neuphoria Therapeutics, resulting in a Nasdaq listing. — A Nasdaq listing significantly increases liquidity, visibility, and access to a broader pool of US institutional capital.
+0.60
2
Scancell expects to raise up to $89 million via equity and debt to fund a global phase III trial for its advanced melanoma treatment. — Securing funding for a registrational phase III trial is a critical de-risking event that extends the company's cash runway into 2029.
+0.50
3
The lead asset, iSCIB1+, has received US FDA fast-track designation. — Fast-track status accelerates the regulatory review process, potentially shortening the time to commercialization.
+0.40
4

6 related stories

Proactive Investors
2h ago
hVIVO orderbook more than doubles to £65m as revenue shifts to second half
- biotech
- clinical trials
- pharma
Read

Scancell to join Nasdaq t… — SCLP +0.90 | NewsImpactScreener

Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

What matters in this story

hVIVO orderbook more than doubles to £65m as revenue shifts to second half

Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

What matters in this story

hVIVO orderbook more than doubles to £65m as revenue shifts to second half

How each ticker is affected

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent

Musk keeps Tesla-SpaceX merger speculation alive, cites growing overlap

Northrim BanCorp, Inc. Signs Definitive Agreement to Acquire PBCO Financial Corporation

Union Pacific and CN Reach Agreement to Expand Customer Opportunities in Connection with Merger

Anglo American shares jump as copper cost guidance cut sharply

Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

What matters in this story

Next reads from the same story arc

hVIVO orderbook more than doubles to £65m as revenue shifts to second half

Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

What matters in this story

Next reads from the same story arc

hVIVO orderbook more than doubles to £65m as revenue shifts to second half

How each ticker is affected

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent

Musk keeps Tesla-SpaceX merger speculation alive, cites growing overlap

Northrim BanCorp, Inc. Signs Definitive Agreement to Acquire PBCO Financial Corporation

Union Pacific and CN Reach Agreement to Expand Customer Opportunities in Connection with Merger

Anglo American shares jump as copper cost guidance cut sharply